Indian Pharmaceutical Supplier to Saudi Arabia.
Saudi Arabia is the largest single pharmaceutical market in the GCC, with SFDA-registered imports flowing through Jeddah Islamic Port, King Abdullah Port and the three international airports at Jeddah, Riyadh and Dammam. M Care ships into the Kingdom for NUPCO-framework tenders, the Ministry of National Guard Health Affairs, Prince Sultan Military Medical City, the King Faisal Specialist Hospital network and Johns Hopkins Aramco Healthcare in the Eastern Province, plus the private-sector chains serving the Riyadh, Makkah and Eastern clusters under the Vision 2030 reorganisation.
Inside the SFDA registration route.
The Saudi Food and Drug Authority is the single gate. A CTD dossier submitted through the SFDA electronic portal typically clears scientific review inside 10 to 12 months, with the pricing committee and final marketing-authorisation issuance adding another two to six. Generics referencing a prior GCC filing move faster; biologicals and high-price specialty molecules go through the pricing committee's full reference-country benchmarking and can stretch to 18 months. The SFDA publishes its price list publicly, which means commercial planning has to assume competitive pricing pressure on every new launch.
Serialisation is mandatory. The RSD (Rx Serialisation and Drug Tracking) platform requires every commercial pack to carry a unique 2D Data Matrix encoding GTIN, batch, expiry and serial number. Upload to the RSD platform happens before dispatch, with reconciliation at landing. M Care runs serialisation integration from the Mumbai packaging floor, so Kingdom-bound lots leave India with the full RSD file already committed.
Arabic labelling follows the SFDA's specific format: outer-carton bilingual, patient information leaflet bilingual, prescriber leaflet where applicable. Controlled substances and psychotropic agents require a separate SFDA narcotic permit issued in parallel with the standard import licence. The GCC joint registration option, coordinated through the Gulf Health Council, uses KSA as the natural anchor for any supplier planning a multi-market launch.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capabilities, pre-assembled.
SFDA CTD dossier preparation
Regulatory writers assemble the Saudi Module 1, the ICH-aligned Modules 2-5, and the pricing-committee pack. Variations, renewals and PSURs maintained against the SFDA submission calendar, with change-control feeding straight to your importer of record.
RSD serialisation
2D Data Matrix generation at the Mumbai packaging line, GTIN allocation, artwork coordination with the SFDA spec, and pre-dispatch upload to the Rx Serialisation and Drug Tracking platform. Parent-child aggregation for case and pallet handled in-line.
NUPCO tender response
Full technical and financial bid pack for National Unified Procurement Company framework tenders, including pricing submission, stability data, GMP certificates, samples and post-award documentation. Separate response tracks for cluster-level parallel procurement.
Hospital-group direct supply
Named-account supply to the Ministry of National Guard Health Affairs, Prince Sultan Military Medical City, King Faisal Specialist Hospital and Research Centre, Johns Hopkins Aramco Healthcare, Dallah Hospital, Saudi German Hospitals and the Dr. Sulaiman Al Habib Medical Group.
GCC anchor registration
Strategic KSA-first filings engineered to extend into the wider GCC via the Gulf Health Council joint pathway, cutting six to eight months off the combined timeline for UAE, Kuwait, Oman, Qatar, Bahrain and Yemen.
SFDA Arabic artwork
Arabic typesetting with medical review by native Arabic-speaking pharmacists, outer-carton and PIL bilingual layout, and SFDA artwork notification handled before any master print run is authorised.
Three air gateways, two deep-water ports.
Air freight: BOM-JED lands at King Abdulaziz International Airport, the primary gateway for western-region distribution including the Makkah cluster. BOM-RUH runs to King Khalid International Airport for Riyadh-cluster supply, and BOM-DMM serves King Fahd International Airport for the Eastern Province including Aramco Healthcare. Block flight times run four to five hours; door-to-door for ambient cargo typically completes in three to five working days including SFDA clearance.
Sea freight: Nhava Sheva to Jeddah Islamic Port or King Abdullah Port (KAP) runs a nine-to-twelve-day direct sailing with Maersk, MSC and CMA CGM offering weekly services. King Abdullah Port, launched in 2014 and now one of the fastest-growing container facilities in the region, offers reduced dwell times compared with the older Jeddah terminals. East-coast imports move through Dammam's King Abdulaziz Port, which serves the Eastern cluster and the industrial cities.
Cold-chain: validated 2-8 active containers from Envirotainer are standard on biologicals above USD 10,000 invoice value; va-Q-tec passive containers cover 15-25 ambient. Bonded stock can be positioned at the Riyadh Dry Port or at bonded warehouses adjacent to King Abdullah Port, with release triggered on NUPCO or hospital call-off. Clearance through the SFDA's e-SAKTA import system takes 48-72 hours once RSD reconciliation matches the dispatch file.
Payment: first-time customers transact on documentary LC at sight through Riyad Bank, Al Rajhi or SABB. Repeat customers move to TT 30% advance, 70% against scanned BL; NUPCO framework awards pay on 60-90 day open account against government undertaking.
What we ship most into Saudi Arabia.
Cardiometabolic disease is the defining burden. Saudi adult diabetes prevalence runs near 18%, hypertension near 15%, and the NUPCO framework tenders carry enormous rolling volumes of metformin, glimepiride, gliclazide, SGLT2 inhibitors, telmisartan-amlodipine combinations and rosuvastatin. These move alongside GLP-1 analogues where the importer holds cold-chain.
Oncology is the second volume driver, with the King Faisal Specialist Hospital, the Princess Noura Oncology Centre and the Aramco cancer programmes running on a mix of innovator and biosimilar supply. Supportive care (ondansetron, palonosetron, pegfilgrastim, filgrastim) ships in steady cadence alongside cytotoxics. Anti-infectives follow a high-volume curve driven by Hajj and Umrah seasonality, with broad-spectrum antibiotics and antivirals peaking around the pilgrimage calendar.
Critical-care and anaesthesia injectables, paediatric antimalarials for Hajj preparedness, dermatology (driven by the largest per-capita cosmetic-derm market in the region), and ophthalmology round out the formulary. Every SKU ships with SFDA-compliant bilingual artwork and an RSD-uploaded serial file.
A Riyadh-cluster tertiary hospital group appointed M Care as secondary supplier for its cardiometabolic formulary in 2023. Over 18 months we delivered 32 shipments covering nine molecules with zero RSD reconciliation failures and an average landed-cost variance of 0.3% against quoted price. The group's head of pharmacy flagged documentation turnaround as the single biggest improvement over the previous incumbent, with PSUR response time down from 14 working days to three.
Why Indian pharma, why M Care, and what you actually get.
India supplies a significant share of Saudi Arabia's generic pharmaceutical imports by volume, and SFDA statistics consistently place Indian manufacturing sites in the top tier of approved foreign facilities. The case is built on three pillars: WHO-GMP depth that matches the SFDA inspection appetite, API backward-integration that holds finished-product prices competitive against the SFDA reference-pricing bracket, and English-language regulatory documentation that feeds the SFDA CTD Module 1 with minimal rework.
The operational question is which Indian supplier can actually service a Saudi account through the full regulatory and procurement cycle. SFDA inspection readiness, RSD serialisation integration, pricing-committee pack preparation, NUPCO bid compliance and cluster-level parallel procurement do not forgive improvisation. M Care runs the Mumbai head office as the regulatory engine: CTD writing, CMC review, stability co-ordination, pharmacovigilance literature monitoring, RSD serial management, and QP release all happen in the same building under the same quality management system. The Dubai commercial desk sits three hours' flight from Riyadh and acts as the relationship face to Saudi importers, tender consultants and hospital pharmacy heads. The London desk handles the European-origin audit trail for customers who want a UK-QP verification layer on top of the Indian certification.
Three specifics matter when you compare suppliers. First, the single-point account manager model: your procurement office has one named contact who owns the file end-to-end, not a rotating pool passing the ticket forward. Second, GCC joint-market dossiers: filings are structured to extend a KSA registration into the five other GCC markets through the Gulf Health Council route, which takes six to eight months off combined-market launch timelines. Third, CTD readiness: dossiers are built eCTD-compliant from submission one, so SFDA variations, GHC extensions and downstream UK or EU filings reuse the same source pack without retrofit cost.
What you avoid with M Care: serialisation failures that strand containers at King Abdullah Port, missing pricing-committee annexes that pause an SFDA file for six months, and the last-minute PSUR scramble that erodes a tender bid. What you get: WHO-GMP-sourced product, audit-ready paperwork, a GCC desk that can be in Riyadh by the next morning flight, and a Mumbai engine room that treats a NUPCO award with the discipline of a clinical-supply contract.
Saudi pharmaceutical import: common questions.
What is the SFDA and how does it differ from GCC-level registration?
The Saudi Food and Drug Authority is the national regulator for drugs, devices, food and cosmetics in the Kingdom. It sits alongside, not inside, the GCC Gulf Health Council. A SFDA-only registration authorises Saudi distribution; a GHC central registration, accepted by all six GCC states, uses KSA among its reference markets but extends approval region-wide.
How does pricing approval work for a new drug in KSA?
The SFDA Pricing Committee benchmarks ex-factory prices against a list of reference countries (GCC neighbours, UK, France, Canada and others) and issues a maximum wholesale and retail price. The committee's decision is a mandatory gate between scientific approval and marketing authorisation issuance.
What does RSD serialisation require at the packaging line?
A unique 2D Data Matrix per commercial pack encoding GTIN, batch, expiry and serial number. Aggregation data for shipper and pallet. File upload to the Rx Serialisation and Drug Tracking platform before dispatch, with EPCIS-aligned event records. We integrate this at the Mumbai packaging floor rather than retrofit at landing.
Can M Care support cluster-level procurement under Vision 2030?
Yes. Clusters such as Riyadh 1, Riyadh 2, Riyadh 3, Eastern, Makkah and Madinah now run parallel procurement alongside NUPCO. We register each SKU centrally, respond to cluster RFQs in parallel, and coordinate delivery into cluster-specific distribution centres as required.
Which Saudi banks handle your documentary transactions?
Riyad Bank, Al Rajhi Bank, Saudi National Bank and SABB are our working first-tier counterparties for sight and usance LCs. We accept documentary credits issued by any A-rated Saudi bank and can work against bank guarantees for NUPCO performance bonds.
How do you handle the Hajj and Umrah demand surge?
We pre-build a seasonal inventory plan from January each year covering antibiotics, antivirals, antipyretics, rehydration salts and chronic-disease continuity packs. Shipments phase into Jeddah through March-June, with a safety-stock buffer held at a bonded facility inside the Makkah cluster's reach.
Do you support the Saudi Ministry of National Guard Health Affairs tender calendar?
Yes. MNGHA runs its own hospital network, including King Abdulaziz Medical City in Riyadh and Jeddah. Tender submission requires SFDA registration, RSD readiness, full stability and a commercial offer keyed to the SFDA price list. We have responded to MNGHA frameworks alongside NUPCO submissions.
Why buyers choose M Care for the India → Saudi Arabia corridor.
SFDA fluency
Dossiers built to the exact format SFDA reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → RUH direct air for time-critical orders, and Jeddah Islamic Port for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in Saudi Arabia.
Top categories we ship to Saudi Arabia
Anti-infectives
Penicillins, cephalosporins, carbapenems, antivirals, antimalarials — 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
Oncology
Cytotoxics, targeted therapy and supportive care — bortezomib, docetaxel, paclitaxel, gemcitabine.
Diabetes & endocrine
Insulins, oral antidiabetics, thyroid and hormonal therapy — 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals — 1,283 SKUs, our broadest catalogue.
Molecule, volume, target buyer. One working day to a quote.
Your enquiry goes directly to the account manager responsible for Saudi Arabia. Whether it is a NUPCO framework, a cluster RFQ or a single private-hospital PO, you get the same working-day turnaround.
Start a Saudi Arabia enquiry → Back to all markets